Biomatics Capital is a venture capital firm that invests in transformational, data-enabled innovation at the intersection of healthcare and technology. The Seattle-based firm focuses on early-stage companies in genomics, digital health, diagnostics, and therapeutics.
43% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (43% of deals). Average disclosed round size is $72.1M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$300M
Top Stage
Series A
Last 12 Mo
0
Team
BN
Boris Nikolic
Managing Director
JS
Julie Sunderland
Managing Director
SR
Saif Rehman
Research Analyst
TH
Taylor Harris
Analyst Intern
EE
Emma Every
Summer Intern
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Encodia | Series C | $75M | Jan 2021 |
 Omniome | Series C | $60M | Jan 2020 |
| TThrive Earlier Detection | Series A | $110M | May 2019 |
 Aledade | Series B | $20M | Jan 2017 |
| VVerve Therapeutics | Series B | $94M | — |
 BlackThorn Therapeutics | Series A | $14M | — |
 Compass Therapeutics | Series A | $132M | — |
Top Co-Investors
GV5 shared
ARCH Venture Partners4 shared
Primary Venture Partners3 shared
Decent Capital2 shared
Altitude Life Science Ventures2 shared
Pivotal Life Sciences2 shared
Alexandria Venture Investments2 shared
Maryland Venture Fund1 shared
Venrock1 shared
Domain Associates1 shared
Mangrove Capital Partners1 shared
Tao Capital Partners1 shared
Northpond Ventures1 shared
Deerfield1 shared
Casdin Capital1 shared
Wellington Management1 shared
Cormorant Asset Management1 shared
Logos Capital1 shared
Alphabet Inc.1 shared
Surveyor Capital1 shared
Last updated: 9 September 2026